A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Thomas Jefferson University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
HUYABIO International, LLC.
Kyowa Kirin Co., Ltd.
University of Nebraska
University of Nebraska
Eastern Cooperative Oncology Group
Atara Biotherapeutics
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Roswell Park Cancer Institute
Mayo Clinic
National Cancer Institute (NCI)
Mayo Clinic
Fred Hutchinson Cancer Center
Roswell Park Cancer Institute
Mayo Clinic
Roswell Park Cancer Institute
Eli Lilly and Company
University of Chicago
Wake Forest University Health Sciences
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Massachusetts General Hospital
Fred Hutchinson Cancer Center
University of Washington
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Mayo Clinic
Alliance for Clinical Trials in Oncology
Columbia University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
City of Hope Medical Center
INSYS Therapeutics Inc
Northside Hospital, Inc.
Vanderbilt-Ingram Cancer Center
Mayo Clinic